Cytotoxic effects of treosulfan on prostate cancer cell lines

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2403-2408

  Feyerabend, Susan ^a   Feil, Gerhard ^a   Krug, Jutta ^a   Kassen, Annette ^b   Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MEDAC GMBH   (Germany)

Author keywords

Cytotoxicity; DU145; LNCaP; PC3; Prostate carcinoma; Treosulfan

Indexed keywords

TREOSULFAN;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTOXICATION; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 34547788287     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bray F, Sankila R, Ferlay J and Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38: 99-166, 2002.
2. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167: 528-534, 2002.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520, 2004.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Thoedore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
5. Boehmer A, Anastasiadis A, Feyerabend S, Nagele U, Kuczyk K, Schilling D, Corvin S, Merseburger A and Stenzl A: Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single center experience. Anticancer Res 25: 4481-4486, 2005.
6. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D and Gleave ME: A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97(17): 1287-1296, 2005.
7. Bhandari MS, Petrylak DP and Hussain M: Clinical trials in metastatic prostate cancer - has there been real progress in the past decade? Eur J Cancer 41(6): 941-953, 2005.
8. Dreicer R, Klein EA, Elson P, Peereboom D, Byzova T and Plow EF: Phase II trial of GM-CSF+thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 23(2): 82-86, 2005.
9. Beinart G, Rini BI, Weinberg V and Small EJ: Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 4(1): 55-60, 2005.
10. Feit PW, Rastrup-Andersen N and Matagne R: Studies on epoxide formation from (2S,3S)-threitol-1,4-bismethane-sulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol-4-methanesulfonate. J Med Chem 13: 1173-1175, 1970.
11. Hartley JA, O'Hare CC and Baumgart J: DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 79: 264-266, 1999.
12. Breitbach GP, Villena C, Schwickerath J, Kunz T, Hurst U, Schmidt-Rhode P, Friederich EJ, Artmeyer E, Schröder M, Eberl M, Framck J, Meinen K, Schiller S, Wenicke K, Sasse G, Schmid H and Bastert G: Treosulfan bei fortgeschrittenem Ovarialcarcinom: Eine Phase III-Studie (abstract). Arch Gynecol Obstet 225(Suppl 1): 80, 1994.
13. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhäuser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, Bojko, Wolf HH, Schindler AE and Seeber S: Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral-blood stem-cell transplantation in patients with advanced malignancies. Clin Cancer Res 6(11): 4209-4216, 2000.
14. Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S and Scheulen ME: Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 45(6): 483-488, 2000.
15. Meden H, Wittkop Y and Kuhn W: Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Anticancer Res 17: 2221-2224, 1997.
16. Banzhaf A, Meden H, Grospietsch G and Kuhn W: Orale Chemotherapie mit Treosulfan bei Patientinnen mit Ovarialkarzinom im Stadium III und IV nach klinischer Komplettremission (abstract). Arch Gynecol Obstet 261(Suppl 1): 117, 1998.
17. Meier W and du Bois A: Palliative therapeutische Möglichkeiten beim Ovarialkarzinom. Onkologe 4: 1153-1158, 1998.
18. Gropp M, Meier W and Hepp H: Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 71: 94-98, 1998.
19. Masding J, Sarkar TK, White WF, Barley VL, Chawla SL, Boesen E, Rostom AY and Menday AP: Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol 97(4): 342-351, 1990.
20. Szelenyi H, Thiel E, Niederle N and Keilholz U: A Phase I trial of gemcitabine and treosulfan to overcome multidrug resistance in patients with advanced solid tumors (abstract). Proc ASCO 18: abstr. 880, 1999.
21. Casper J, Knauf W and Kiefer T: Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103: 725-731, 2004.
22. Harstrick A, Wilke H, Eberhardt W, Klaasen U, Strumberg D, Kom M, Scheulen ME, Baumgart J and Seeber S: A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 19: 153-156, 1996.
23. Kassen A, Sutkowski DM, Ahn H, Sensibar JA, Kozlowski JM and Lee C: Stromal cells of the human prostate: initial isolation and characterization. Prostate 28(2): 89-97, 1996.
24. Spieth K, Kaufmann R and Gille J: Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 52(5): 377-382, 2003.
25. Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B and Nilsson S: Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 44(6): 644-650, 2005.
26. Teicher BA: Antitumor alkylating agents. In: Cancer, Principles and Practice of Oncology. DeVita V, Helman S, Rosenberg SA (eds.). Philidelphia, Lippincoft-Raven, 5th edition, pp. 405-406, 1997.
27. Meinhardt G, Dayyani F, Jahrsdorfer B, Baumgart J, Emmerich B and Schmidmaier R: Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 122: 892-899, 2003.
28. Park S and Tretyakova N: Structural characterization of the major DNA-DNA cross-link of 1,2,3,4 - diepoxybutane. Chem Res Toxicol 17(2): 129-136, 2004.
29. Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J, Seeber S and Scheulen ME: Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 42(2): 99-104, 1998.
30. Welsh J, Stuart JFB, Soukop M, Cunningham D, Blackie R, Sangster G and Caiman KC: The pharmacokinetics of oral and i.v. treosulfan (abstract). Br J Cancer 46: 467, 1982.